• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

SART Data: Does Preimplantation Genetic Testing Increase the Risk of Adverse Pregnancy or Neonatal Outcomes?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Li et al. (AJOG, 2021) assessed the relationship between preimplantation genetic testing (PGT) and risk for adverse perinatal outcomes of singleton pregnancies conceived following frozen embryo transfer

METHODS:

  • Retrospective analysis
  • Data source
    • The Society for Assisted Reproductive Technology (SART) Clinical Outcomes Reporting System
    • Cycles initiated between 2014 and 2015
  • Population
    • Autologous frozen embryo transfer cycles that led to singleton live births
  • Exposure
    • PGT
  • Study design
    • Multivariable linear regression analyses were used for the birthweight and Z-score and logistic regression for the binary outcomes
    • Covariates adjusted for: Year of transfer | Maternal age | BMI | Smoking status | Obstetrical history | Infertility diagnosis | Infant sex
  • Primary outcomes
    • Birthweight
    • Birthweight Z-score (SD above or below the mean)
    • Small for gestational age (SGA)
    • Large for gestational age (LGA)
    • Macrosomia
    • Preterm birth

RESULTS:

  • 16,246 frozen embryo transfers were analyzed
    • PGT: 6244 transfers
    • No testing: 10,002 transfers

Maternal characteristics

  • Women from the PGT group were older (P< 0.001)
    • Testing: 35.8 years
    • No testing: 33.7 years
  • Women from the PGT group had a higher prevalence of prior spontaneous abortion (P< 0.001)
    • Testing 37.3%
    • No testing: 27.7%

Outcomes Following Adjustment

  • PGT was associated with increased risk for preterm birth
    • Adjusted odds ratio 1.20 (95% CI, 1.09 to 1.33; P < 0.001)
    • Seen in both unadjusted and adjusted calculations
  • No differences were identified between groups for the following
    • Birthweight
      • –14.63 g (95% CI, –29.65 to 0.38; P = 0.056)
    • Birthweight Z-score
      • –0.03 (95% CI, –0.06 to 0.00; P = 0.081)
    • Odds of SGA
      • aOR 1.17 (95% CI, 0.99 to 1.38; P = 0.066)
    • Odds of LGA
      • aOR 0.96 (95% CI, 0.88 to 1.06; P = 0.418)
    • Odds of macrosomia
      • aOR 0.96 (95% CI, 0.85 to 1.07; P = 0.427)
  • Subgroup analysis based on infertility diagnosis did not change the above results

CONCLUSION:

  • PGT was associated with approximately a 20% higher risk of preterm birth in frozen embryo transfer cycles
  • Other adverse perinatal outcomes were not found in this cohort
  • The authors conclude

Although the optimal utilization of PGT in IVF is debated, PGT may lower the risk of a pregnancy with a fetus with a single-gene disorder or aneuploidy

To better gauge the relative risks and benefits of this technique in clinical practice, the perinatal outcomes related to PGT procedures should continue to be examined

Learn More – Primary Sources:

Embryo biopsy and perinatal outcomes of singleton pregnancies: an analysis of 16,246 frozen embryo transfer cycles reported in the Society for Assisted Reproductive Technology Clinical Outcomes Reporting System

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Does Preimplantation Genetic Testing for Monogenetic Diseases Increase the Risk of Pregnancy Complications?
Does Noninvasive Screening Result in Fewer Miscarriages When Compared to Amniocentesis?
How Does NIPT Compare to Invasive Testing in the Setting of Ultrasound Abnormalities?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site